Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATETM study of ibrutinib vs ofatumumab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma

In the phase III study RESONATETM, ibrutinib reduced the risk of progression and improved overall survival vs ofatumumab in previously treated patients with CLL/SLL. In this novel analysis of patient well-being including patient-reported outcomes, ibrutinib reduced disease burden while preserving parameters of hematologic and immunologic function in RESONATE. These results suggest that ibrutinib can improve QoL while prolonging survival.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 17, 2018 Category: Hematology Authors: Jacqueline C. Barrientos, Susan O'Brien, Jennifer R. Brown, Neil E. Kay, Nishitha M. Reddy, Steven Coutre, Constantine Tam, Stephen Mulligan, Ulrich Jaeger, Stephen Devereux, Christopher Pocock, Tadeusz Robak, Stephen J. Schuster, Anna Schuh, Devinder Gil Tags: Original Study Source Type: research